BUSINESS

• Biogen Enters Exclusive Option Agreement for Acute Stroke Treatment with Japanese Biotech
  June 12, 2018

• Astellas Launches Tablet Formulations of Xtandi
  June 12, 2018

• Takeda Inks US$7.5 billion Term Loan Credit to Refinance M&A Bridge
  June 11, 2018

• FY2017 Earnings Roundup - 4: Japan Makers Struggling to Recoup R&D Investments, New Value-Generating Model Is a Must
  June 8, 2018

• Bayer Establishes Asia’s 1st “CoLaborator” in Kobe for Use by Startups
  June 8, 2018

• FY2017 Earnings Roundup - 3: Top 3 Japan Generic Makers Pursuing Diversified Overseas Strategies
  June 7, 2018

• Shionogi’s Single-Dose Flu Med Xofluza Heavily Promoted in March: Anterio
  June 7, 2018

• Olmesartan Lawsuit Settlement in US Now Valid: Daiichi Sankyo
  June 7, 2018

• Nobelpharma’s Rapalimus Now Available in Japan
  June 7, 2018

• Pexidartinib Delivers Significant ORR in PIII: Daiichi Sankyo
  June 6, 2018

• Takeda’s Founding Family-Backed Shareholders Demand Prior Vote for 1 Trillion Yen-Plus Deals
  June 6, 2018

• AbbVie Japan Seeks Hidradenitis Suppurativa Nod for Humira
  June 6, 2018

• Yakult Honsha Obtains Rights to Hematologic Cancer Agent from US Biopharma
  June 6, 2018

• Rxulti Earns European Panel Nod for Schizophrenia: Otsuka/Lundbeck
  June 5, 2018

• FY2017 Earnings Roundup - 2: Global Brands Gaining Further Traction, Some Notch Better-than-Expected Growth
  June 5, 2018

• AstraZeneca Japan Settles All Labor Suits
  June 4, 2018

• Meiji Seika Pharma Chief Sounds Negative about Authorized Generic Biz
  June 4, 2018

• JCR to Launch Japan PIII for BBB-Penetrating Hunter Syndrome Drug
  June 4, 2018

• FY2017 Earnings Roundup - 1: Major Japan Makers Braced for Gloomier Year Ahead at Home, See 4.4% Dip
  June 4, 2018

• Japan Drug Makers See Rising Overseas Sales Ratio amid Uphill Battle at Home: Tally
  June 1, 2018

ページ

• « 先頭
• ‹ Prev
• …
• 392
• 393
• 394
• 395
• 396
• 397
• 398
• 399
• 400
• …
• Next ›
• 最終 »